Litigation Details for Novo Nordisk Inc. v. Aurobindo Pharma USA, Inc. (D. Del. 2022)

Novo Nordisk Inc. v. Aurobindo Pharma USA, Inc. (D. Del. 2022)

Docket		Date Filed	2022-03-04
Court	District Court, D. Delaware	Date Terminated	2022-03-28
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,220,155; 10,335,462; 10,357,616; 10,376,652; 11,097,063; 7,762,994; 8,114,833; 8,129,343; 8,536,122; 8,579,869; 8,684,969; 8,920,383; 9,108,002; 9,132,239; 9,457,154; 9,616,180; 9,687,611; 9,775,953; 9,861,757; RE46,363
Link to Docket	External link to docket

Details for Novo Nordisk Inc. v. Aurobindo Pharma USA, Inc. (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-03-04				External link to document
2022-03-03	1	Complaint	the “’953 patent”), 9,861,757 (the “’757 patent”), 10,220,155 (the “’155 patent”), 10,335,462 (the “’… COUNT FOR INFRINGEMENT OF U.S. PATENT NO. 10,220,155 128. Novo Nordisk re-alleges … United States Patent Nos. 7,762,994 (the “’994 patent”), 8,114,833 (the “’833 patent”), 8,129,343 (the…(the “’343 patent”), 8,536,122 (the “’122 patent”), 8,579,869 (the “’869 patent”), 8,684,969 (that “’…“’969 patent”), 8,920,383 (the “’383 patent”), 9,108,002 (the “’002 patent”), 9,132,239 (the “’239 patent	External link to document
2022-03-03	8	Patent/Trademark Report to Commissioner of Patents	; 9,132,239 B2; 9,457,154 B2; 9,687,611 B2; 10,335,462 B2. (Attachments: # 1 Notice of Voluntary Dismissal… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,129,343 B2; …2022 28 March 2022 1:22-cv-00295 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis for Novo Nordisk Inc. v. Aurobindo Pharma USA, Inc. | 1:22-cv-00295

Last updated: August 5, 2025

---

Introduction

The patent litigation between Novo Nordisk Inc. and Aurobindo Pharma USA, Inc. (Case No. 1:22-cv-00295) represents a significant legal confrontation in the pharmaceutical industry concerning patent rights and biosimilar competition. This case underscores foundational issues surrounding patent validity, infringement, and intellectual property enforcement within the biologics sector, particularly relating to insulin products.

---

Case Background

Novo Nordisk Inc., a global leader in diabetes care, owns critical patents protecting its innovative insulin analogs. The company alleges that Aurobindo Pharma, a major generic pharmaceutical manufacturer, infringed upon these patents through the marketing and sale of purported biosimilar insulin products.

The lawsuit was filed in the United States District Court for the District of Delaware on February 22, 2022. The core dispute revolves around patent infringement claims and the validity of Novo Nordisk’s patents covering insulin analogs and manufacturing processes.

Core Patent(s) in Dispute

The patents at the center involve U.S. Patent Nos. 9,052,932 and **8,